Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Gault LauraOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,500Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Gault LauraOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,250Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Greene Barry EOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:168,000Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Cook Anne MarieOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,500Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Cook Anne MarieOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,250Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Benecchi ChristopherOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,000Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Benecchi ChristopherOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,500Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Iguchi KimiOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,500Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Iguchi KimiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,250Price:--
-
Jan 03, 2024 (filed on Jan 04, 2024)Insider Name:Federer JessicaOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,177Price:--
Filings by filing date
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Gault LauraOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,500Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Gault LauraOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,250Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Greene Barry EOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:168,000Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Cook Anne MarieOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,500Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Cook Anne MarieOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,250Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Benecchi ChristopherOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,000Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Benecchi ChristopherOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,500Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Iguchi KimiOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,500Price:--
-
Feb 13, 2024 (filed on Feb 15, 2024)Insider Name:Iguchi KimiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,250Price:--
-
Jan 03, 2024 (filed on Jan 04, 2024)Insider Name:Federer JessicaOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,177Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 215 1st St CAMBRIDGE MA 02142-1213 |
Tel: | N/A |
Website: | https://www.sagerx.com |
IR: | See website |
Key People | ||
Barry E. Greene President, Chief Executive Officer, Director | Kimi E. Iguchi Chief Financial Officer, Treasurer | Anne Marie Cook Senior Vice President, General Counsel, Corporate Secretary |
Mike Quirk Chief Scientific Officer | Christopher Benecchi Chief Business Officer | Laura Gault Chief Development Officer |
Business Overview |
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor. |
Financial Overview |
For the fiscal year ended 31 December 2023, SAGE Therapeutics Inc revenues increased from $7.7M to $86.5M. Net loss increased 2% to $541.5M. Revenues reflect Product increase of 36% to $10.5M, Collaboration revenue - related party increase from $0K to $824K. Higher net loss reflects Restructuring increase from $0K to $33.4M (expense), R & D exp increase of 10% to $331.4M (expense), Labor & Related Expenses in SGA increase of 23% to $108.2M (expense). |
Employees: | 487 as of Feb 7, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $21.59M as of Dec 31, 2023 |
Annual revenue (TTM): | $86.46M as of Dec 31, 2023 |
EBITDA (TTM): | -$545.07M as of Dec 31, 2023 |
Net annual income (TTM): | -$541.49M as of Dec 31, 2023 |
Free cash flow (TTM): | -$541.14M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 60,106,687 as of Feb 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |